Here is what CAN happen. 2nd example shows the obvious: When you have a clear large addressable market, things can easily go ballistic!
Amplia Therapeutics (ASX: ATX)
Share Price Increase: Rose 190% in a single day on June 19, 2025, contributing to significant gains over the six-month period.
Market Cap: Approximately $30–50 million (small-cap range, exact figure not specified in sources but inferred from context).
Reason for Rise: The surge was driven by positive news from the ongoing ACCENT trial for its novel drug narmafotinib, targeting advanced pancreatic cancer. The company announced a second complete response, indicating strong clinical progress and boosting investor confidence in its potential to address a high-unmet-need cancer. Context: Amplia’s focus on a novel FAK inhibitor positions it as a speculative but high-potential player in oncology, attracting attention from biotech investors.
LTR Pharma (ASX: LTR)
Share Price Increase: Up 442% over the past six months (as of October 2024, with momentum likely sustained into 2025 based on ongoing developments).
Market Cap: Approximately $70–100 million (based on share price and issued capital updates from 2024).
Reason for Rise: LTR Pharma’s nasal spray, Spontan, for erectile dysfunction, gained traction after successful clinical trials showing faster onset (9 minutes vs. 56 minutes for traditional tablets). Australian medical providers began prescribing it under the Therapeutic Goods Administration’s Special Access Scheme in August 2024. Additionally, a $10.5 million capital raise in July 2024 and a co-development agreement for global markets in August 2024 fueled investor enthusiasm. Context: The unique delivery mechanism and first-to-market advantage in Australia for Spontan have positioned LTR as a high-growth prospect in men’s health.
Market Context: The ASX biotech and pharma sector has seen increased investor interest due to its potential for high returns, despite inherent risks. The sector’s total market cap reached $252 billion across 178 companies by March 2024, indicating a robust ecosystem. However, small-cap biotechs are highly volatile, often driven by clinical trial outcomes, regulatory approvals, or partnerships. Challenges and Risks: Recent market volatility, including US tariff threats impacting Australian pharmaceutical exports (e.g., CSL’s 6% drop in April 2025), may have indirectly benefited smaller, domestically focused biotechs less exposed to international trade risks.
(20min delay)